Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Common Equity (2011 - 2026)

Lite Strategy (LITS) posted Common Equity of $56.8 million for Q1 2026, down 30.56% on a QoQ basis from $81.8 million in Q4 2025, and up 190.86% year-over-year from $19.5 million in Q1 2025.

Analysis

Lite Strategy (LITS) Common Equity (2011 - 2026) Analysis & Trends

Lite Strategy has reported Common Equity for 16 years, with the latest figure at $56.8 million in Q1 2026.

  • On a quarterly basis, Common Equity rose 190.86% year-over-year to $56.8 million in Q1 2026; TTM through Mar 2026 was $56.8 million, a 190.86% increase from a year earlier, with the FY2025 full-year figure at $16.9 million, down 48.73% from the prior year.
  • Common Equity was $56.8 million for Q1 2026 at Lite Strategy, down from $81.8 million in the prior quarter.
  • The five-year high for Common Equity was $112.3 million in Q3 2025, with the low at $16.9 million in Q2 2025.
  • Average Common Equity over 5 years is $48.5 million, with a median of $48.4 million recorded in 2022.
  • The sharpest annual moves came in 2024 and 2025: Common Equity plunged 69.42% in 2024, then jumped 351.28% in 2025.
  • Over 5 years, Common Equity stood at $48.4 million in 2022, then grew by 22.98% to $59.5 million in 2023, then sank by 62.85% to $22.1 million in 2024, then jumped by 270.4% to $81.8 million in 2025, then slumped by 30.56% to $56.8 million in 2026.
  • The last three Common Equity figures came in at $56.8 million (Q1 2026), $81.8 million (Q4 2025), and $112.3 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 11.69 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 11.83 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 20.25 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 31.71 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 8.42 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 6.76 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 1.35 Bn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 18.85 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 4.92 Bn
10 Lite Strategy 38.03 Mn 30.49 Mn - 56.84 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 56.84 Mn
Dec 31, 2025 81.85 Mn
Sep 30, 2025 112.27 Mn
Jun 30, 2025 16.93 Mn
Mar 31, 2025 19.54 Mn
Dec 31, 2024 22.10 Mn
Sep 30, 2024 24.88 Mn
Jun 30, 2024 33.02 Mn
Mar 31, 2024 51.03 Mn
Dec 31, 2023 59.49 Mn
Sep 30, 2023 81.36 Mn
Jun 30, 2023 24.62 Mn
Mar 31, 2023 34.35 Mn
Dec 31, 2022 48.37 Mn
Sep 30, 2022 37.31 Mn
Jun 30, 2022 52.41 Mn
Mar 31, 2022 67.81 Mn
Dec 31, 2021 73.33 Mn
Sep 30, 2021 34.30 Mn
Jun 30, 2021 49.47 Mn